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Abstract
Background: Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a
promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal
models of Alzheimer’s disease (AD) with initiation at a late disease stage. Thus, we aimed to investigate the effects
of interventional late-stage Anle138b treatment, which previously indicated great potential to inhibit oligomer
accumulation by binding of pathological aggregates, on the metabolic decline in transgenic mice with established
tauopathy in a longitudinal 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) study.
Methods: Twelve transgenic mice expressing all six human tau isoforms (hTau) and ten controls were imaged by
FDG-PET at baseline (14.5 months), followed by randomization into Anle138b treatment and vehicle groups for 3
months. FDG-PET was repeated after treatment for 3 months, and brains were analyzed by tau
immunohistochemistry. Longitudinal changes of glucose metabolism were compared between study groups, and
the end point tau load was correlated with individual FDG-PET findings.
Results: Tau pathology was significantly ameliorated by late-stage Anle138b treatment when compared to vehicle
(frontal cortex − 53%, p < 0.001; hippocampus − 59%, p < 0.005). FDG-PET revealed a reversal of metabolic decline
during Anle138b treatment, whereas the vehicle group showed ongoing deterioration. End point glucose
metabolism in the brain of hTau mice had a strong correlation with tau deposition measured by
immunohistochemistry (R = 0.92, p < 0.001).
Conclusion: Late-stage oligomer modulation effectively ameliorated tau pathology in hTau mice and rescued
metabolic function. Molecular imaging by FDG-PET can serve for monitoring effects of Anle138b treatment.
Keywords: Tau, Neuronal injury, Late-stage, Anle138b, Small animal PET
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: matthias.brendel@med.uni-muenchen.de
†Matthias Brendel, Maximilian Deussing and Tanja Blume contributed equally
to this work.
1Department of Nuclear Medicine, University Hospital, LMU Munich,
Marchioninistr.15, 81377 Munich, Germany
Full list of author information is available at the end of the article
Brendel et al. Alzheimer's Research & Therapy           (2019) 11:67 
https://doi.org/10.1186/s13195-019-0522-z
Background
Neurofibrillary tangles constitute one of the most char-
acteristic neuropathological findings in Alzheimer’s dis-
ease (AD), which is the most frequent form of dementia,
and tangles likewise occur in certain non-AD dementias
known collectively as tauopathies [1]. Several in vivo in-
vestigations have confirmed a strong link between the
presence of hyperphosphorylated tau in the brain, which
self-aggregates to paired helical tau filaments and neuro-
fibrillary tangles [2], and future metabolic and cognitive
declines in preclinical AD [3–5]. Thus, there is great im-
petus to develop effective interventions against tau de-
position in AD and other neurodegenerative diseases.
Preventive treatment strategies with small molecular
weight oligomer modulators of tau, which comprise a suit-
able pharmacokinetic profile and possess good brain pene-
trance [6], present one promising pharmacological
approach to ameliorate tau pathology. This strategy has
shown early success in inhibiting tau aggregation in vitro
and in reducing 4R tau aggregates in P301S mice, which
serve as a model for tau-positive frontotemporal dementia
[7]. The same treatment also attenuated intracerebral ac-
cumulations of α-synuclein in a mouse model of Parkin-
son’s disease [8] and β-amyloid in AD model mice [9].
However, there has hitherto been no direct confirm-
ation of beneficial impacts of oligomer modulator
treatment on brain function and tau protein accumu-
lation in transgenic mice expressing human tau pro-
tein. Furthermore, the efficacy of late-stage oligomer
modulation which emulates a more relevant clinical
setting is also unproven.
Molecular brain imaging with 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET) is a powerful
in vivo tool for revealing metabolic deficits in neurode-
generative diseases and has now attained acceptance in
the clinical diagnosis of AD [10–12]. Longitudinal FDG-
PET is also fit for the preclinical assessment of neuronal
injury in a mouse model of tauopathy [13]. Given this
background, we aimed to perform an interventional
treatment study with the novel aggregation-inhibiting
oligomer modulator Anle138b in transgenic mice ex-
pressing all six human tau isoforms (hTau), thus consti-
tuting a murine model of AD tauopathy [14]. We
initiated the treatment at a late disease stage character-
ized by the presence of tau aggregates, thus emulating a
likely clinical scenario. Our main end point for testing
the effectiveness of the treatment was serial monitoring
of cerebral metabolism by FDG-PET. In addition, we
made an end point immunohistochemical assessment of
the density of tau pathology after 3 months’ treatment
with Anle138b as compared to untreated hTau mice.
Finally, we undertook a correlational analysis of the rela-
tionship between individual tau pathology with longitu-
dinal metabolic decline to FDG-PET.
Materials and methods
Animals and study design
All experiments were carried out in compliance with the
German national guidelines for animal protection
(TierSchG, Germany) and with approval of the local ani-
mal care committee (Regierung von Oberbayern), under
supervision by a veterinarian. Experiments, analyses, and
reporting were performed in accordance with the AR-
RIVE guidelines [15]. Animals were housed in a
temperature- and humidity-controlled environment with
a 12-h light–dark cycle, with free access to food (Ssniff,
Soest, Germany) and water. Sample size calculation
(G*Power, V3.1.9.2, University of Kiel, Germany) was
based on earlier FDG-PET estimates in mice and assum-
ing a type I error α = 0.05, a power of 0.8, and a dropout
rate of 15% during follow-up. Assuming a relevant treat-
ment effect of 5%, we calculated a group size of six, in-
cluding one mouse for dropout compensation.
Twelve hTau mice and ten controls (all female) were
purchased from Jackson Laboratories (JAX®) at 3months
of age and housed in our pathogen-free animal facility
until attaining 14.5months of age. We then undertook
baseline FDG-PET imaging and randomized the mice into
Anle138b treatment and vehicle treatment groups (n = 6/
5 each). hTau mice had been designed to express all six
isoforms of human tau in similar ratios to that in the dis-
eased human brain, but do not express significant amount
of mouse tau [14]. The model was generated by crossing
8c mice that express a tau transgene derived from a hu-
man P1-derived artificial chromosome, H1 haplotype [16]
together with tau knock-out mice that have a targeted dis-
ruption of exon one of the tau gene [17].
The hTau mice that we used are homozygous for Mapt
<tm1(EGFP)Klt> and heterozygous for Tg (NAPT)8cPdav,
whereas controls only contain the homozygous Mapt <
tm1(EGFP)Klt> mutation. Anle138b treatment was
administered for 3months, and follow-up PET imaging
was performed in the last week of treatment. After a visual
quality check of PET images, we performed transcardial
perfusion with fixation in 4% paraformaldehyde and brain
extraction for immunohistochemical analyses.
Anle138b treatment
We used the oligomer modulator Anle138b ([3-(1,3-benzo-
dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole]) [6] as a
therapeutic against tau deposition. The compound was for-
mulated in food pellets (Ssniff, Soest, Germany) at a con-
centration of 2 g/kg pellets [7], which were administered ad
libitum over a period of 3months. The food composition
was based on regular maintenance diet (16.2MJ/kg; 9% fat,
24% protein, 67% carbohydrates). Detailed specifications of
the Anle138b formulation can be found in supplement #2
of [6]. In brief, (1-(1,3-benzodioxol-5-yl)-3-(3-bromophe-
nyl)propane-1,3-dione), a previously reported pyrazole title
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compound [18], was used as a precursor for the chemical
synthesis of Anle138b in several steps. Control mice were
fed with unmodified food pellets.
PET imaging
PET data acquisition and analyses
All PET procedures followed standardized, established
protocols [19]. In brief, mice were anesthetized with iso-
flurane (1.5%, delivered at 3.5 l/min) and placed in the
aperture of the Siemens Inveon DPET [20] as described
previously [21]. Mice had been fasted for at least 3 hours
prior to tracer administration. Static FDG-PET imaging
from 30 to 60min p.i. was performed after administration
of 13.2 ± 2.1MBq 18F-FDG as previously established [19].
The emission recording was followed by a 15-min trans-
mission scan using rotating 57Co point sources. The image
was reconstructed as a single 30-min frame in 4 OSEM3D
and 32 MAP 3D iterations, giving a target resolution of
1.0 mm and a zoom factor of 1.0, with scatter-, attenu-
ation-, and decay-correction, resulting in a final voxel di-
mension of 0.78 × 0.78 × 0.80mm. Following recovery
from anesthesia, mice were returned to their home cages.
PET post-processing
FDG-PET images (30–60min) were co-registered to an
MRI mouse brain atlas [22] by a manual rigid-body trans-
formation (TXrigid) using the PMOD fusion tool (V3.5,
PMOD Technologies Ltd.). A reader who was blind to the
type of mouse confirmed the initial registration. Then, we
applied a reader-independent co-registration by generating
treatment group-specific standard FDG-PET templates in
the MRI atlas space. Non-linear brain normalization was
performed with the PMOD fusion tool for each individual
co-registered image to obtain a transformation matrix
(TXBrainNorm) for each mouse brain to the template. The
manual (TXrigid) and automatic (TXBrainNorm) transforma-
tions were concatenated and applied to the native space
μPET data to guarantee a minimum of interpolation. As
the μPET templates had been initially aligned to the atlas,
all final fused μPET images had the same spatial orienta-
tion and voxel dimensions as the MRI mouse brain atlas,
i.e., 0.064 × 0.064 × 0.064mm.
PET analysis
An oval-shaped frontal cortical volume of interest (VOI;
28 mm3) and a bilateral circular-shaped hippocampal
VOI (11 mm3) defined in the MRI atlas were placed on
the resampled image to calculate the mean radioactivity
concentrations in standardized uptake value (SUV)
units. Absence of tau pathology in the brainstem of hTau
mice has been shown earlier [14], justifying its use as a
reference tissue in this mouse model. We calculated the
SUV ratios (SUVRBST) as the ratio of the radioactivity
concentrations in target and brainstem reference VOIs
of the Mirrione atlas implemented in PMOD [23]. Lon-
gitudinal changes were computed for each mouse as the
absolute difference of SUVR values between baseline
and follow-up scans (ΔSUVR).
Immunohistochemical analyses
After removal from the skull, brains were bisected at the
midline and one cerebral hemisphere randomly selected
for immunohistochemical analysis after fixation by
immersion in 4% paraformaldehyde at 4 °C for 24 h. A
mean of three representative 50-μm-thick slices per ani-
mal was then cut in the sagittal plane between 1.5 and
2.0 mm from the midline using a vibratome (VT 1000 S,
Leica, Wetzlar, Germany). Free-floating sections were
permeabilized with 2% Triton X-100 overnight and then
blocked with I-Block™ Protein-Based Blocking Reagent
(Thermo Fischer Scientific). We obtained immunohisto-
chemical labelling of hTau using the CP13 primary anti-
body (dilution; 1:25, 48 h, RT), which binds specifically
to phosphorylated serine 202 (pS202) on tau, followed
by incubation with the A-21244 secondary antibody,
which contains Alexa Fluor 647 dye (Invitrogen, 1:500)
[16, 24]. The unbound dye was removed by three wash-
ing steps with PBS, and the slices were then mounted on
microscope slides with fluorescent mounting medium
(Dako, Germany). Images were acquired with an
inverted confocal Laser-Scanning Microscope LSM510=
NLO (Zeiss). We imaged the frontal cortex and hippo-
campus of each slice three-dimensionally in tile scan
mode, which allows automatic stitching of an array of
fields of view. Tau load (%) in maximum intensity pro-
jected image stacks was calculated as the summed area
of all tau-positive cells identified using an automated in-
tensity threshold relative to the total inspected area in
ImageJ software (Wayne Rasband, (NIH)). Second, we
calculated the number of CP13-positive neurons per area
(N/mm2) in the cortex and the hippocampus. The oper-
ator was blind to the PET results.
Statistics
Statistics were performed using SPSS (V25, IBM Cooper-
ation) and GraphPad Prism (V5.03). FDG-PET measures
of baseline, follow-up assessment, and longitudinal
changes, as well as tau burden (%), the number of tau-po-
sitive neurons per area and body weight, were compared
between the three groups of treated hTau mice, vehicle
hTau mice, and non-carrier controls by a one-way
ANOVA including Tukey post hoc correction for multiple
comparisons. Longitudinal FDG-PET measures in the
treatment group were also tested voxel-wise (paired t test)
by a statistical parametric mapping approach [25] to allow
a region-independent evaluation of metabolic rescue. Body
weight was compared by an unpaired Student’s t test. For
inter-modality correlation analyses, Pearson coefficients of
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correlation (R) were calculated between region-specific tau
area (%) values and PET read-outs (SUVR, ΔSUVR). A Sha-
piro–Wilk test was performed to verify normal distribution
of sample values (results are provided in Additional file 1).
In all tests, a threshold of p < 0.05 was considered to be sig-
nificant for rejection of the null hypothesis.
Results
Late-stage Anle138b treatment reduces tau deposition in
hTau mice
First, we investigated if late-stage Anle138b treatment ex-
tending over 3months has the potential to reduce further
tau accumulation in mice expressing human AD tau. One
mouse of the hTau treatment group died during the baseline
PET scan, and one mouse of the hTau vehicle group died
between baseline and follow-up, resulting in equally sized
groups of five mice for both of the treatment and vehicle
groups (carrier and non-carrier). Body weight was initially
18% lower in hTau mice compared to non-carriers at base-
line (p = 0.003), but there were no significant differences be-
tween treatment and vehicle groups at subsequent times
(see Additional file 1). CP13 immunohistochemical staining
revealed a clear visual reduction of tau deposition in hTau
mice receiving Anle138b treatment when compared to the
hTau vehicle group (Fig. 1a–d). Immunohistochemical
quantitation indicated a 53% reduction of tau burden after
3months of Anle138b treatment in the frontal cortex, rela-
tive to the burden in hTau vehicle mice (6.1% vs. 13%; p <
0.001, Fig. 1e). Similarly, there was 59% less tau burden in
the hippocampus of the treated mice (1.9% vs 4.7; p < 0.001,
Fig. 1f). There were fewer CP13-positive neurons in the
Anle138b treatment group in the frontal cortex (− 33%; p <
0.001, Fig. 1g) and the hippocampus (− 14%; p < 0.001,
Fig. 1g) when compared to the hTau vehicle group.
There was no detectable tau accumulation in non-car-
rier control mice, irrespective of Anle138b treatment.
Table 1 gives a detailed overview of immunohistochemis-
try findings together with PET findings presented below.
Metabolic decline is rescued by late-stage Anle138b
treatment
Next, we aimed to elucidate if late-stage Anle138b treat-
ment has the potential to prevent or rescue metabolic
decline. Relative to non-carrier controls, the hTau mice
A B
C
E F G H
D
Fig. 1 Distinct reduction of CP13-positive tau profiles by late-stage Anle138b treatment in hTau mice. Representative immunohistochemistry
images of the frontal cortex (a, b) and the hippocampus (c, d) are shown for hTau mice after 3 months treatment with Anle138b or vehicle.
Quantification indicated significant reductions of tau load and CP13-positive neurons in the frontal cortex (e, g) and the hippocampus (f, h). Error
bars represent SEM
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already exhibited moderately reduced relative cerebral
FDG uptake at 14.5 months of age (baseline) in the
frontal cortex (SUVR − 9%, p = 0.025) and in the hippo-
campus (SUVR − 10%, p = 0.020) (Fig. 2). The drug
intervention provoked a significant rescue of cerebral
metabolism in the frontal cortex of treated hTau mice
(ΔSUVR + 6%), whereas the vehicle-treated hTau mice
showed further metabolic deterioration (ΔSUVR − 7%,
p = 0.048; Table 1, Fig. 2). There was likewise a trend to-
wards recovery of metabolism in the hippocampus of
treated hTau mice (ΔSUVR + 6% vs − 5%, p = 0.162;
Table 1). Non-carrier controls did not show any signifi-
cant changes in cerebral metabolism during the observa-
tion period, nor was there any main effect of Anle138b
treatment on metabolism (Table 1).
For a region-independent statistical analysis of the po-
tential metabolic rescue, we performed a voxel-wise lon-
gitudinal comparison between individual baseline and
follow-up FDG SUVR images in the hTau Anle138b
treatment group. This analysis revealed significant
(p < 0.01, unc k > 20) clusters of increasing relative
metabolism in the hippocampus (16,204 voxels, 4.3
mm3, TPEAK 19.2), the somatomotor cortex (18,532
voxels, 4.9 mm3, TPEAK 13.8), the frontal pole (15,268
voxels, 4.0 mm3, TPEAK 14.2), and the thalamus (9594
voxels, 2.5 mm3, TPEAK 8.9) (Fig. 3). Increasing relative
cerebral metabolism upon Anle138b treatment was
evident to visual inspection of SUVR images in indi-
vidual hTau mice (Fig. 3).
Vehicle-treated hTau mice showed a strong loss of
relative cerebral metabolism in the frontal cortex (− 13%,
p < 0.001) and the hippocampus (− 12%, p = 0.007) at
17.5 months when compared to non-carrier controls. On
the other hand, there was only a non-significant trend
towards metabolic decline in the same contrast for the
hTau Anle138b treatment group (− 6%, p = 0.101, hippo-
campus − 5%, p = 0.369).
Tau pathology and metabolic decline are closely
associated in hTau mice
Finally, we asked if our observations of attenuated meta-
bolic decline in the treated mice are indeed attributable to
reduced tau deposition. To test this, we performed a cor-
relation analysis between read-outs of FDG-PET SUVR
and tau burden in both of our target areas. Importantly,
end point tau burden as assessed by immunohistochemis-
try in the frontal cortex had an extraordinarily strong
negative correlation with the corresponding end point
FDG-PET signal within the complete group of hTau mice
(R = − 0.92, p < 0.001, Fig. 4a). There were also negative
correlations when considering the hTau vehicle (R = −
0.90, p = 0.036) or the hTau treatment group (R = − 0.90,
p = 0.035) separately, meaning that metabolic function de-
teriorated in concert with tau deposition. Furthermore, we
also observed a negative association between the longitu-
dinal change of relative FDG uptake and the end point tau
burden (R = − 0.77, p = 0.010, Fig. 4c), which gives add-
itional evidence for the interrelationship of the two
Table 1 Comprehensive overview of end point immunohistochemistry and longitudinal FDG-PET findings in treated and untreated
hTau mice
hTau Anle138b hTau Vehicle hTau pooled Baseline Non-carrier controls (pooled)
Immunohistochemistry
Frontal cortex (%-area)
6.1 ± 1.9** 12.9 ± 1.8 0
Immunohistochemistry
Frontal cortex (CP13+ neurons, N/mm2)
1366 ± 116** 2039 ± 153 0
Immunohistochemistry
Hippocampus (%-area)
1.9 ± 1.4** 4.8 ± 0.4 0
Immunohistochemistry
Hippocampus (CP13+ neurons, N/mm2)
534 ± 18** 619 ± 13 0
FDG-PET baseline
Frontal cortex (SUVR)
0.97 ± 0.02 1.02 ± 0.09 1.00 ± 0.07# 1.10 ± 0.10
FDG-PET follow-up
Frontal cortex (SUVR)
1.03 ± 0.05* 0.95 ± 0.03# 1.09 ± 0.06
FDG-PET change
Frontal cortex (ΔSUVR)
+ 0.06 ± 0.06* − 0.07 ± 0.09 + 0.01 ± 0.05
FDG-PET baseline
Hippocampus (SUVR)
0.93 ± 0.03 0.98 ± 0.10 0.96 ± 0.08# 1.06 ± 0.10
FDG-PET follow-up
Hippocampus (SUVR)
1.00 ± 0.07 0.93 ± 0.05## 1.05 ± 0.07
FDG-PET change
Hippocampus (ΔSUVR)
+ 0.06 ± 0.05 − 0.05 ± 0.10 + 0.00 ± 0.05
Results summary: “*” indicates p < 0.05 and “**” indicates p < 0.005 in the direct comparison of hTau treatment and vehicle groups. “#” indicates p < 0.05 and “##”
indicates p < 0.005 in the comparison of hTau groups (pooled baseline or treatment/vehicle during follow-up) versus non-carrier controls
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biomarkers. End point FDG-PET (R = 0.81, p = 0.004) and
longitudinal changes of relative FDG uptake (R = 0.69,
p = 0.026) were also negatively correlated with the number
of CP13-positive neurons in the neocortex, when consid-
ering all hTau mice. Findings in the hippocampus mir-
rored the results for the frontal cortex, but with lesser
correlations (Fig. 4b, d, f, h).
Discussion
We present the first study documenting an in vivo proof of
rescued metabolic function to longitudinal FDG-PET in
mice expressing human tau after receiving a late-stage
oligomer modulator treatment. Furthermore, our end point
immunohistochemical data give clear evidence that tau
deposition was reduced in treated mice, in proportion to
the rescue from metabolic decline. Thus, Anle138b holds
promise to improve even established decline of glucose
consumption by promoting reduction of CP13-positive
hyperphosphorylated tau aggregates and less neurons with
CP13-positive tau accumulation, which may bode well for
future translational interventional studies of human AD.
Anle138b is already of proven efficacy in lowering tau
deposition in the 4R mouse PS19 tauopathy model and
caused an increased survival rate in these mice, when
administered in chow from weaning to terminal disease
[7]. The aim of the current study was to prove the drug’s
performance when initiated rather as a late-stage treat-
ment of tauopathy in an AD-like mouse model charac-
terized by paired helical 3R/4R tau and slow disease
progression resembling aspects of the human disease
[14]. Late-stage initiation seems more relevant to trans-
lation into clinical testing, as patients will likely have an
already established tau load at the time of diagnosis. Tau
deposition in the neocortex and the hippocampus of our
A
B C
Fig. 2 Serial FDG-PET imaging of relative cerebral metabolism (SUVR): Cerebral metabolism to FDG-PET improved at follow-up imaging 3months
after initiating late-stage Anle138b treatment in hTau mice when compared to own baseline, with an already established baseline reduction in
comparison to non-carrier control mice (a, compare both upper rows). On the other hand, we saw ongoing metabolic decline in the vehicle-
treated hTau group (a, compare both lower rows). Quantification of longitudinal changes in relative FDG uptake (ΔSUVR) to PET indicates
normalization of cerebral metabolism with prolonged Anle138b administration, but ongoing decrease in the frontal cortex (b) and the
hippocampus (c) in the hTau vehicle group. Non-carrier controls do not show any relevant changes of relative FDG uptake over time. Data are
adjusted for baseline imaging. BL baseline at 14.5 months of age, FU follow-up at 17.5 months. Error bars represent SEM
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hTau mice was more than halved by Anle138b treatment
(− 53%/− 59%) in comparison to vehicle fed mice, an ef-
fect consistent with earlier observations in similarly
treated PS19 mice. Thus, we observed the anticipated
beneficial effect of Anle138b oligomer modulator treat-
ment on AD-like tau pathology also for this paradigm of
late-stage treatment initiation. Nevertheless, the regional
distribution of pathology and neuronal dysfunction in
these hTau mice (neocortical and hippocampal) closely
reflects the topology of human AD tau deposition. In
contrast, PS19 tauopathy mice primarily exhibit path-
ology in the hindbrain, which leads to early death due to
motor impairment and respiratory failure [26]. The re-
gional pattern of tau deposition in our hTau mice also
matched the pattern of baseline FDG-PET deficits,
which clearly indicated reduced relative FDG uptake in
the hippocampus and frontal cortex, already evident at
the baseline examination at 14.5 months (Fig. 2a).
The feasibility of detection and monitoring loss of
cerebral metabolism by serial FDG-PET in tau model
mice was also well-supported by a recent study [13]
showing decreased FDG-PET uptake in transgenic tau-
VWL mice already at 11 months, which further pro-
gressed to 19months of age. Therefore, we aimed in the
present study to untangle a crucial question: does an
intervention against the primary pathology caused by
the transgene in the mouse model rescue or rectify the
AD-like metabolic decline, where reduced FDG uptake
is a surrogate for progressive failure of neuronal func-
tion? This is an important consideration in light of sev-
eral failed AD vaccination trials targeting β-amyloid
pathology [27, 28], which succeeded in clearing the ther-
apy target from the brain but failed to improve cognition
as their primary end point. The association between cog-
nitive performance and neuronal dysfunction/injury is
modulated by diverse factors and moderated by cogni-
tive reserve [29]. In this regard, biomarkers of neuronal
injury are important read-outs, as they resemble the de-
sired functional therapy outcome. FDG-PET, which
traces cerebral glucose consumption, is widely used for
the assessment of neuronal injury and diagnosis of neu-
rodegenerative diseases [30] and has served for therapy
monitoring in AD drug trials [31]. Most diagnostic
schemes of AD employed by international working
groups now include biomarkers of neuronal injury to-
gether with Aβ and tau protein deposition [10–12]. Pre-
clinical FDG-PET imaging has the clear advantage of
delivering robust values even in individual mice and al-
lows adjustment for varying baseline measures [19].
Our findings of attenuated metabolic decline with
Anle138b treatment initiated at a late disease stage are
compelling as they show inhibition or even dispersal of
established tau aggregates, along with rebound of the pre-
viously impaired cerebral metabolism (Fig. 3). This means
Fig. 3 Voxel-wise analysis of metabolic rescue in the Anle138 treatment group: Direct comparison between follow-up and baseline FDG-PET
imaging by statistical parametric mapping of SUVR maps (upper row) as a region-independent analysis. Green coding (coronal slices upon an MRI
template) indicates voxels with a significant increase during Anle138b treatment whereas red coding indicates voxels with a significant decrease
(p < 0.01; unc; k > 20). SUVR PET images of an individual example are illustrated for baseline (middle row) and follow-up (lower row) time points
and show a visually discernible increasing glucose metabolism during treatment
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Fig. 4 (See legend on next page.)
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that the loss of brain energy metabolism arising from tau
pathology is recoverable to some degree after rectifying
the tauopathy. In clinical translation, sporadic AD patients
will likely initiate treatment at an established disease stage,
similar to our late-stage treatment paradigm as tau path-
ology is already established in mild cognitive impairment.
Thus, the ability to halt or even improve metabolic func-
tion at late disease stages is an invaluable property for
drugs targeting tau pathology, as in the present Anle138b
study of tauopathy mice. This stands in contrast to pre-
clinical results with γ-secretase-modulation and β-secre-
tase-inhibition, which clearly lost their effectiveness once
amyloid β-amyloid pathology was established [32, 33].
Nevertheless, potential differences between the mouse
model and the situation in human AD need to be consid-
ered for interpretation of the results as the investigated
mouse model exhibits only tau pathology, without β-amyl-
oid accumulation. Thus, it might be more difficult to halt
or improve metabolic decline by late-stage AD treatment
in humans, given that the onset of tau pathology is likely
triggered by initial amyloid accumulation [34].
Importantly, we find a clear negative association be-
tween the end point tau burden in the brain of hTau
mice and the extent of impaired cerebral metabolism
to longitudinal FDG-PET (Fig. 4). These data support
a physiological linkage between AD-like tau pathology
and metabolic decline. The rescue of metabolic de-
cline after initiating oligomer treatment strengthens
further this mechanistic concept. Previous human
studies using PET and assays of tau in cerebrospinal
fluid [3, 4] also suggested an association between tau
pathology and metabolic decline, despite lacking the
histopathological gold standard assessments. Thus, to
our knowledge, we provide the first demonstration of
a direct correlation between metabolic decline and
AD tau deposition, as assessed by gold standard im-
munohistochemistry. Interestingly, the neocortical
FDG uptake of the two hTau mice with lowest tau
pathology after Anle138b treatment attained the range
of non-carrier control mice (Fig. 4a). Future studies
with large sample sizes might be able to define a
threshold of tau pathology manifesting in neuronal
dysfunction. Keeping in mind earlier investigations
showing a direct linkage between metabolic changes
and tau phosphorylation [35], we note as a limitation
that we cannot entirely rule out a direct influence of
the observed metabolic changes in FDG-PET on the
rate of tau phosphorylation. Subsequently, alterations
of pS202 phosphorylation could have had an impact
on the intensity of the CP13 immunohistochemical
staining, which was however qualitatively similar in
the CP13-positive neuronal population. However, we
also observed a clear treatment effect on the number
of CP13-positive neurons, and we do not deem it
likely that some non-specific treatment effect on glo-
bal metabolic changes would completely ameliorate
the CP13 signal of single neurons.
Future preclinical studies of Anle138b treatment might
properly include tau PET to allow longitudinal monitoring
of tau pathology in hTau mice. We previously established
18F-THK5117 PET in different tau mouse models [25],
but were unable to see specific PET signal in untreated
hTau mice even at 17.5months of age (data not shown).
This failure probably relates to the rather high detection
threshold of first-generation tau PET ligands (~ 10%) and
the very low magnitude of advanced forms of tau (dis-
cussed below) in hTau mice, which represent the target of
arylquinoline tau ligands. Nonetheless, the current devel-
opment of second-generation tau PET ligands [36] with
reduced off-target binding and higher signal to noise ratio
will potentially solve this technical issue. Recent establish-
ment of the SV2A PET assay of synaptic density [37]
might further enhance future study designs by affording a
more direct index of synaptic integrity compared to FDG-
PET. Although the FDG-PET signal is a valid surrogate for
synaptic activity [38], it can also be altered by factors such
as neuroinflammation or blood glucose levels. The current
results call for inclusion of spatial learning tasks in future
Anle138b studies with larger sample sizes.
Among the limitations of our study, we note that for
technical reasons biochemical analyses of tau concentra-
tion were unavailable. Furthermore, tau pathology was
only assessed by a single immunohistochemical measure
targeting pS202, since Gallyas staining did not give a spe-
cific tau signal in this material (data not shown). The
apparently negative Gallyas staining in untreated hTau
mice at 17.5months of age suggests only that there was
an unexpectedly low degree of advanced tau aggregate
forms in these mice. We speculate that our housing of the
transgenic mice in a pathogen-free environment for more
(See figure on previous page.)
Fig. 4 Correlation analysis of metabolic function and end point tau assessments: The end point tau burden and the number of CP13-positive
neurons per unit area in the frontal cortex had strong negative correlations with end point findings (a, e) and longitudinal changes (c, g) of
normalized FDG uptake in hTau mice. Corresponding plots for the hippocampus indicate the same negative correlation between tau burden and
region-specific relative glucose metabolism (b, d, f, h). Purple trendlines show the linear association within the hTau treatment group, whereas
the gray trendline provides the linear association for the hTau vehicle group. The dashed black line illustrates the linear association of combined
hTau mice. Associated R2 values are indicated in the same color. Solid and dotted lines of non-carrier controls show mean ± SEM
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than 10months before imaging might have had an impact
on the severity of pathology expressed in this model.
Conclusion
Late-stage initiation of oligomer modulation by Anle138b
effectively ameliorated AD-like tau pathology in hTau
mice while rescuing the declining cerebral metabolism to
FDG-PET. Late-stage treatments with efficacy despite
established brain pathology at the initiation of treatment
are highly desirable for AD, and the present preclinical re-
sults are encouraging for the use of agents like Anle138b.
Additional file
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measures of body weight. (DOCX 16 kb)
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